Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new ...
Clearside eye disease candidate aces exam in pursuit of Roche's Vabysmo and Regeneron, Bayer's Eylea
A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...
Unlike chimeric antigen receptor (CAR) T-cell therapies, which can identify surface antigens, TCR-T cell therapies like ...
Istaroxime is a novel first-in-class investigational therapy that is intended to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining ...
Additional positive data from the Company’s completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports ...
The annual meeting of the American Society for Radiation Oncology was held from Sept. 29 to Oct. 2 in Washington, D.C., ...
A new tool detects the evolutionary advantages of multiple myeloma cells over the different treatments available. The information it provides can help prevent the tumor from becoming resistant to ...
The investigational IL-17A inhibitor izokibep was found to induce clear clinical responses in people with moderate to severe ...
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed ...
A phase I trial found that the next-generation yellow fever vaccine (vYF) triggers immune responses and offers safety similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback